EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. 2012

J J M van Dongen, and L Lhermitte, and S Böttcher, and J Almeida, and V H J van der Velden, and J Flores-Montero, and A Rawstron, and V Asnafi, and Q Lécrevisse, and P Lucio, and E Mejstrikova, and T Szczepański, and T Kalina, and R de Tute, and M Brüggemann, and L Sedek, and M Cullen, and A W Langerak, and A Mendonça, and E Macintyre, and M Martin-Ayuso, and O Hrusak, and M B Vidriales, and A Orfao, and
Department of Immunology, Erasmus MC, University Medical Center Rotterdam (Erasmus MC), Rotterdam, The Netherlands. j.j.m.vandongen@erasmusmc.nl

Most consensus leukemia & lymphoma antibody panels consist of lists of markers based on expert opinions, but they have not been validated. Here we present the validated EuroFlow 8-color antibody panels for immunophenotyping of hematological malignancies. The single-tube screening panels and multi-tube classification panels fit into the EuroFlow diagnostic algorithm with entries defined by clinical and laboratory parameters. The panels were constructed in 2-7 sequential design-evaluation-redesign rounds, using novel Infinicyt software tools for multivariate data analysis. Two groups of markers are combined in each 8-color tube: (i) backbone markers to identify distinct cell populations in a sample, and (ii) markers for characterization of specific cell populations. In multi-tube panels, the backbone markers were optimally placed at the same fluorochrome position in every tube, to provide identical multidimensional localization of the target cell population(s). The characterization markers were positioned according to the diagnostic utility of the combined markers. Each proposed antibody combination was tested against reference databases of normal and malignant cells from healthy subjects and WHO-based disease entities, respectively. The EuroFlow studies resulted in validated and flexible 8-color antibody panels for multidimensional identification and characterization of normal and aberrant cells, optimally suited for immunophenotypic screening and classification of hematological malignancies.

UI MeSH Term Description Entries
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005060 Europe The continent north of AFRICA, west of ASIA and east of the ATLANTIC OCEAN. Northern Europe,Southern Europe,Western Europe
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D016130 Immunophenotyping Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry. Lymphocyte Immunophenotyping,Lymphocyte Subtyping,Immunologic Subtyping,Immunologic Subtypings,Lymphocyte Phenotyping,Subtyping, Immunologic,Subtypings, Immunologic,Immunophenotyping, Lymphocyte,Immunophenotypings,Immunophenotypings, Lymphocyte,Lymphocyte Immunophenotypings,Lymphocyte Phenotypings,Lymphocyte Subtypings,Phenotyping, Lymphocyte,Phenotypings, Lymphocyte,Subtyping, Lymphocyte,Subtypings, Lymphocyte
D019337 Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES. Blood Cancer,Hematologic Malignancies,Hematopoietic Neoplasms,Hematologic Malignancy,Hematological Malignancies,Hematological Neoplasms,Hematopoietic Malignancies,Malignancies, Hematologic,Malignancy, Hematologic,Neoplasms, Hematologic,Neoplasms, Hematopoietic,Blood Cancers,Cancer, Blood,Hematologic Neoplasm,Hematological Malignancy,Hematological Neoplasm,Hematopoietic Malignancy,Hematopoietic Neoplasm,Malignancy, Hematological,Malignancy, Hematopoietic,Neoplasm, Hematologic,Neoplasm, Hematological,Neoplasm, Hematopoietic

Related Publications

J J M van Dongen, and L Lhermitte, and S Böttcher, and J Almeida, and V H J van der Velden, and J Flores-Montero, and A Rawstron, and V Asnafi, and Q Lécrevisse, and P Lucio, and E Mejstrikova, and T Szczepański, and T Kalina, and R de Tute, and M Brüggemann, and L Sedek, and M Cullen, and A W Langerak, and A Mendonça, and E Macintyre, and M Martin-Ayuso, and O Hrusak, and M B Vidriales, and A Orfao, and
August 1996, Leukemia,
J J M van Dongen, and L Lhermitte, and S Böttcher, and J Almeida, and V H J van der Velden, and J Flores-Montero, and A Rawstron, and V Asnafi, and Q Lécrevisse, and P Lucio, and E Mejstrikova, and T Szczepański, and T Kalina, and R de Tute, and M Brüggemann, and L Sedek, and M Cullen, and A W Langerak, and A Mendonça, and E Macintyre, and M Martin-Ayuso, and O Hrusak, and M B Vidriales, and A Orfao, and
January 2006, Clinical chemistry and laboratory medicine,
J J M van Dongen, and L Lhermitte, and S Böttcher, and J Almeida, and V H J van der Velden, and J Flores-Montero, and A Rawstron, and V Asnafi, and Q Lécrevisse, and P Lucio, and E Mejstrikova, and T Szczepański, and T Kalina, and R de Tute, and M Brüggemann, and L Sedek, and M Cullen, and A W Langerak, and A Mendonça, and E Macintyre, and M Martin-Ayuso, and O Hrusak, and M B Vidriales, and A Orfao, and
June 2022, Veterinary immunology and immunopathology,
J J M van Dongen, and L Lhermitte, and S Böttcher, and J Almeida, and V H J van der Velden, and J Flores-Montero, and A Rawstron, and V Asnafi, and Q Lécrevisse, and P Lucio, and E Mejstrikova, and T Szczepański, and T Kalina, and R de Tute, and M Brüggemann, and L Sedek, and M Cullen, and A W Langerak, and A Mendonça, and E Macintyre, and M Martin-Ayuso, and O Hrusak, and M B Vidriales, and A Orfao, and
December 1997, Leukemia,
J J M van Dongen, and L Lhermitte, and S Böttcher, and J Almeida, and V H J van der Velden, and J Flores-Montero, and A Rawstron, and V Asnafi, and Q Lécrevisse, and P Lucio, and E Mejstrikova, and T Szczepański, and T Kalina, and R de Tute, and M Brüggemann, and L Sedek, and M Cullen, and A W Langerak, and A Mendonça, and E Macintyre, and M Martin-Ayuso, and O Hrusak, and M B Vidriales, and A Orfao, and
April 2008, Blood,
J J M van Dongen, and L Lhermitte, and S Böttcher, and J Almeida, and V H J van der Velden, and J Flores-Montero, and A Rawstron, and V Asnafi, and Q Lécrevisse, and P Lucio, and E Mejstrikova, and T Szczepański, and T Kalina, and R de Tute, and M Brüggemann, and L Sedek, and M Cullen, and A W Langerak, and A Mendonça, and E Macintyre, and M Martin-Ayuso, and O Hrusak, and M B Vidriales, and A Orfao, and
January 2022, Cancers,
J J M van Dongen, and L Lhermitte, and S Böttcher, and J Almeida, and V H J van der Velden, and J Flores-Montero, and A Rawstron, and V Asnafi, and Q Lécrevisse, and P Lucio, and E Mejstrikova, and T Szczepański, and T Kalina, and R de Tute, and M Brüggemann, and L Sedek, and M Cullen, and A W Langerak, and A Mendonça, and E Macintyre, and M Martin-Ayuso, and O Hrusak, and M B Vidriales, and A Orfao, and
January 2002, Journal of biological regulators and homeostatic agents,
J J M van Dongen, and L Lhermitte, and S Böttcher, and J Almeida, and V H J van der Velden, and J Flores-Montero, and A Rawstron, and V Asnafi, and Q Lécrevisse, and P Lucio, and E Mejstrikova, and T Szczepański, and T Kalina, and R de Tute, and M Brüggemann, and L Sedek, and M Cullen, and A W Langerak, and A Mendonça, and E Macintyre, and M Martin-Ayuso, and O Hrusak, and M B Vidriales, and A Orfao, and
June 1992, European journal of pediatrics,
J J M van Dongen, and L Lhermitte, and S Böttcher, and J Almeida, and V H J van der Velden, and J Flores-Montero, and A Rawstron, and V Asnafi, and Q Lécrevisse, and P Lucio, and E Mejstrikova, and T Szczepański, and T Kalina, and R de Tute, and M Brüggemann, and L Sedek, and M Cullen, and A W Langerak, and A Mendonça, and E Macintyre, and M Martin-Ayuso, and O Hrusak, and M B Vidriales, and A Orfao, and
January 1999, Acta clinica Belgica,
J J M van Dongen, and L Lhermitte, and S Böttcher, and J Almeida, and V H J van der Velden, and J Flores-Montero, and A Rawstron, and V Asnafi, and Q Lécrevisse, and P Lucio, and E Mejstrikova, and T Szczepański, and T Kalina, and R de Tute, and M Brüggemann, and L Sedek, and M Cullen, and A W Langerak, and A Mendonça, and E Macintyre, and M Martin-Ayuso, and O Hrusak, and M B Vidriales, and A Orfao, and
August 2004, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Copied contents to your clipboard!